[1] Younossi ZM, Koenig AB, Abdelatif D, et al. Epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64:73-84.
[2] Sanyal AJ, Friedman SL, McCullough AJ,et al; American Association for the Study of Liver Diseases; United States Food and Drug Administration. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology,2015, 61:1392-1405.
[3] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases. Hepatology,2018, 67: 328-357.
[4] Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 2017,65: 1557-1565.
[5] Younossi ZM , Loomba R, Rinella ME,et al.Current and future therapeutic regimens for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology,2018, 68: 361-371. |
